{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:08:49Z","timestamp":1790744929001,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T00:00:00Z","timestamp":1456185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12325-016-0292-y","type":"journal-article","created":{"date-parts":[[2016,2,23]],"date-time":"2016-02-23T10:11:43Z","timestamp":1456222303000},"page":"345-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients"],"prefix":"10.1007","volume":"33","author":[{"given":"Gorden","family":"Muduma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Odeyemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayne","family":"Smith-Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,23]]},"reference":[{"issue":"23","key":"292_CR1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"RA Wolfe","year":"1999","unstructured":"Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"292_CR2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/ajkd.1998.v32.pm9669429","volume":"32","author":"R Jofr\u00e9","year":"1998","unstructured":"Jofr\u00e9 R, L\u00f3pez-G\u00f3mez JM, Moreno F, Sanz-Guajardo D, Valderr\u00e1bano F. Changes in quality of life after renal transplantation. Am J Kidney Dis. 1998;32(1):93\u2013100.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"292_CR3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.transproceed.2014.12.005","volume":"47","author":"A S\u00e1nchez-Escuredo","year":"2015","unstructured":"S\u00e1nchez-Escuredo A, Alsina A, Diekmann F, et al. Economic analysis of the treatment of end-stage renal disease treatment: living-donor kidney transplantation versus hemodialysis. Transpl Proc. 2015;47(1):30\u20133.","journal-title":"Transpl Proc."},{"issue":"3","key":"292_CR4","first-page":"A4796","volume":"61","author":"CE Jensen","year":"2014","unstructured":"Jensen CE, S\u00f8rensen P, Petersen KD. In Denmark kidney transplantation is more cost-effective than dialysis. Dan Med J. 2014;61(3):A4796.","journal-title":"Dan Med J."},{"key":"292_CR5","unstructured":"NHS Blood and Transplant. Activity report 2014\u20132015. http:\/\/nhsbtmediaservices.blob.core.windows.net\/organdonation-assets\/pdfs\/activity_report_2014_15.pdf . Last accessed 11 Sept 2015."},{"issue":"2","key":"292_CR6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","volume":"12","author":"J Sellar\u00e9s","year":"2012","unstructured":"Sellar\u00e9s J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transpl. 2012;12(2):388\u201399.","journal-title":"Am J Transpl"},{"key":"292_CR7","unstructured":"R\u00e9seau Epid\u00e9miologie Information N\u00e9phrologie. Annual report 2012. http:\/\/www.agence-biomedecine.fr\/IMG\/pdf\/rapport_rein_vdef_2012.pdf . Last accessed 11 March 2015."},{"issue":"10","key":"292_CR8","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/j.1600-6143.2010.03268.x","volume":"10","author":"PF Halloran","year":"2010","unstructured":"Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant. 2010;10(10):2223\u201330.","journal-title":"Am J Transplant"},{"issue":"11","key":"292_CR9","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","volume":"9","author":"G Einecke","year":"2009","unstructured":"Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009;9(11):2520\u201331.","journal-title":"Am J Transplant"},{"issue":"1","key":"292_CR10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","volume":"90","author":"RS Gaston","year":"2010","unstructured":"Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 2010;90(1):68\u201374.","journal-title":"Transplantation"},{"issue":"2","key":"292_CR11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","volume":"14","author":"A Djamali","year":"2014","unstructured":"Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transpl. 2014;14(2):255\u201371.","journal-title":"Am J Transpl"},{"issue":"3","key":"292_CR12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1600-6143.2011.03926.x","volume":"12","author":"M Mengel","year":"2012","unstructured":"Mengel M, Sis B, Haas M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transpl. 2012;12(3):563\u201370.","journal-title":"Am J Transpl"},{"issue":"2","key":"292_CR13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","volume":"14","author":"M Haas","year":"2014","unstructured":"Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transpl. 2014;14(2):272\u201383.","journal-title":"Am J Transpl"},{"issue":"7","key":"292_CR14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1600-6143.2004.00500.x","volume":"4","author":"SK Takemoto","year":"2004","unstructured":"Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transpl. 2004;4(7):1033\u201341.","journal-title":"Am J Transpl"},{"issue":"3","key":"292_CR15","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1681\/ASN.V133779","volume":"13","author":"S Mauiyyedi","year":"2002","unstructured":"Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol. 2002;13(3):779\u201387.","journal-title":"J Am Soc Nephrol"},{"key":"292_CR16","first-page":"193724","volume":"2012","author":"C Puttarajappa","year":"2012","unstructured":"Puttarajappa C, Shapiro R, Tan HP. Antibody-mediated rejection in kidney transplantation: a review. J Transpl. 2012;2012:193724.","journal-title":"J Transpl"},{"key":"292_CR17","first-page":"S1","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Suppl 3. 2009;9:S1\u2013157.","journal-title":"Suppl 3"},{"key":"292_CR18","unstructured":"British Transplantation Society. Clinical Practice Guidelines. Post-operative care of the Kidney Transplant Recipient. February 2011. http:\/\/www.renal.org\/docs\/default-source\/guidelines-resources\/Post-operative_care_of_the_kidney_transplant_recipient_-_Final_Version-_05_February_2011.pdf?sfvrsn=0 . Last accessed 25 March 2015."},{"issue":"2","key":"292_CR19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3324\/haematol.2013.092460","volume":"99","author":"SY Kristinsson","year":"2014","unstructured":"Kristinsson SY, Gridley G, Hoover RN, Check D, Landgren O. Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27\u00a0years follow-up. Haematologica. 2014;99(2):392\u20138.","journal-title":"Haematologica"},{"issue":"2","key":"292_CR20","first-page":"51","volume":"2","author":"G Hychko","year":"2011","unstructured":"Hychko G, Mirhosseini A, Parhizgar A, Ghahramani N. A systematic review and meta-analysis of rituximab in antibody-mediated renal allograft rejection. Int J Organ Transpl Med. 2011;2(2):51\u20136.","journal-title":"Int J Organ Transpl Med."},{"key":"292_CR21","author":"B Sautenet","year":"2015","unstructured":"Sautenet B, Blancho G, B\u00fcchler M, et al. One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial. Transplantation. 2015;. doi: 10.1097\/TP.0000000000000958 .","journal-title":"Transplantation"},{"issue":"6","key":"292_CR22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.6002\/ect.2012.0131","volume":"10","author":"JG Nigos","year":"2012","unstructured":"Nigos JG, Arora S, Nath P, et al. Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen. Exp Clin Transpl. 2012;10(6):609\u201313.","journal-title":"Exp Clin Transpl"},{"issue":"10","key":"292_CR23","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1016\/j.transproceed.2012.02.037","volume":"44","author":"I Tzvetanov","year":"2012","unstructured":"Tzvetanov I, Spaggiari M, Joseph J, et al. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature. Transpl Proc. 2012;44(10):2971\u20135.","journal-title":"Transpl Proc."},{"issue":"3","key":"292_CR24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5414\/CN107156","volume":"77","author":"KK Sureshkumar","year":"2012","unstructured":"Sureshkumar KK, Hussain SM, Marcus RJ, et al. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation. Clin Nephrol. 2012;77(3):246\u201353.","journal-title":"Clin Nephrol"},{"issue":"12","key":"292_CR25","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/TP.0b013e3181fdd9b0","volume":"90","author":"SM Flechner","year":"2010","unstructured":"Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation. 2010;90(12):1486\u201392.","journal-title":"Transplantation"},{"issue":"11","key":"292_CR26","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256\u201364.","journal-title":"Nat Biotechnol"},{"issue":"11","key":"292_CR27","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1111\/j.1600-6143.2011.03757.x","volume":"11","author":"MD Stegall","year":"2011","unstructured":"Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transpl. 2011;11(11):2405\u201313.","journal-title":"Am J Transpl"},{"issue":"9","key":"292_CR28","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.transproceed.2012.09.038","volume":"44","author":"F Gonz\u00e1lez-Roncero","year":"2012","unstructured":"Gonz\u00e1lez-Roncero F, Su\u00f1er M, Bernal G, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transpl Proc. 2012;44(9):2690\u20134.","journal-title":"Transpl Proc."},{"key":"292_CR29","unstructured":"NHS England. Clinical Commissioning Policy: Eculizumab for the treatment of refractory antibody mediated rejection post kidney transplant. January 2014. http:\/\/www.england.nhs.uk\/wp-content\/uploads\/2014\/06\/Eculizumab.pdf . Last accessed 12 March 2015."},{"key":"292_CR30","unstructured":"United States Food and Drug Administration prescribing information for rituximab. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/103705s5432lbl.pdf . Last accessed 11 March 2015."},{"key":"292_CR31","unstructured":"United States Food and Drug Administration prescribing information for eculizumab. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/125166s368s380lbl.pdf . Last accessed 11 March 2015."},{"key":"292_CR32","unstructured":"Edinburgh Renal Unit. Transplant Handbook. Treatment of acute antibody-mediated rejection. http:\/\/www.edren.org\/pages\/handbooks\/transplant-handbook\/immunosuppression-protocol\/treatment-of-acute-antibody-mediated-rejection.php . Last accessed 25 March 2015."},{"issue":"8","key":"292_CR33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/TP.0b013e31825d1587","volume":"94","author":"DM Roberts","year":"2012","unstructured":"Roberts DM, Jiang SH, Chadban SJ. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation. 2012;94(8):775\u201383.","journal-title":"Transplantation"},{"issue":"2","key":"292_CR34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ctr.12491","volume":"29","author":"SA Burton","year":"2015","unstructured":"Burton SA, Amir N, Asbury A, Lange A, Hardinger KL. Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey. Clin Transpl. 2015;29(2):118\u201323.","journal-title":"Clin Transpl"},{"issue":"5","key":"292_CR35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1600-6143.2011.03525.x","volume":"11","author":"P Archdeacon","year":"2011","unstructured":"Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transpl. 2011;11(5):896\u2013906.","journal-title":"Am J Transpl"},{"issue":"3","key":"292_CR36","doi-asserted-by":"crossref","first-page":"A187","DOI":"10.1016\/j.jval.2015.03.1082","volume":"18","author":"W Irish","year":"2015","unstructured":"Irish W, Boscoe A, Ryan MP, Iloeje U, Gunnarsson C, Marks W. Economic burden of antibody mediated rejection following kidney transplantation: comparative analysis using the premier hospital database. Value Health. 2015;18(3):A187.","journal-title":"Value Health."},{"issue":"6","key":"292_CR37","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/TP.0b013e3182802f88","volume":"95","author":"AA Vo","year":"2013","unstructured":"Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation. 2013;95(6):852\u20138.","journal-title":"Transplantation"},{"issue":"4","key":"292_CR38","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.08140910","volume":"6","author":"K Marfo","year":"2011","unstructured":"Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol. 2011;6(4):922\u201336.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"10","key":"292_CR39","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.transproceed.2008.08.131","volume":"40","author":"B Tanriover","year":"2008","unstructured":"Tanriover B, Wright SE, Foster SV, et al. High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis. Transpl Proc. 2008;40(10):3393\u20136.","journal-title":"Transpl Proc."},{"issue":"7","key":"292_CR40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/phar.1426","volume":"34","author":"M Kim","year":"2014","unstructured":"Kim M, Martin ST, Townsend KR, Gabardi S. Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options. Pharmacotherapy. 2014;34(7):733\u201344.","journal-title":"Pharmacotherapy."},{"issue":"12","key":"292_CR41","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3111\/13696998.2015.1074584","volume":"18","author":"G Muduma","year":"2015","unstructured":"Muduma G, Odeyemi I, Pollock RF. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK. J Med Econ. 2015;18(12):1050\u20139.","journal-title":"J Med Econ."},{"issue":"7","key":"292_CR42","doi-asserted-by":"crossref","first-page":"e103568","DOI":"10.1371\/journal.pone.0103568","volume":"9","author":"P Biesenbach","year":"2014","unstructured":"Biesenbach P, Kain R, Derfler K, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption. PLoS One. 2014;9(7):e103568.","journal-title":"PLoS One"},{"issue":"5","key":"292_CR43","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1432-2277.2012.01447.x","volume":"25","author":"C Morath","year":"2012","unstructured":"Morath C, Beimler J, Opelz G, et al. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int. 2012;25(5):506\u201317.","journal-title":"Transpl Int"},{"issue":"4","key":"292_CR44","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.transproceed.2012.09.123","volume":"45","author":"J Gubensek","year":"2013","unstructured":"Gubensek J, Buturovic-Ponikvar J, Kandus A, et al. Plasma exchange and intravenous immunoglobulin in the treatment of antibody-mediated rejection after kidney transplantation: a single-center historic cohort study. Transpl Proc. 2013;45(4):1524\u20137.","journal-title":"Transpl Proc."},{"issue":"2","key":"292_CR45","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/TP.0b013e318222c9c6","volume":"92","author":"M Willicombe","year":"2011","unstructured":"Willicombe M, Roufosse C, Brookes P, et al. Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome. Transplantation. 2011;92(2):176\u201382.","journal-title":"Transplantation"},{"issue":"4","key":"292_CR46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00520-007-0329-5","volume":"16","author":"LS Schwartzberg","year":"2008","unstructured":"Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer. 2008;16(4):393\u20138.","journal-title":"Support Care Cancer"},{"key":"292_CR47","unstructured":"NHS England. Clinical Commissioning Policy: Bortezomib for the treatment of refractory antibody mediated rejection post kidney transplant. January 2014. http:\/\/www.england.nhs.uk\/wp-content\/uploads\/2014\/06\/bortezomib.pdf . Last accessed 31 July 2015."},{"issue":"2","key":"292_CR48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.smim.2011.08.015","volume":"24","author":"MH Levine","year":"2012","unstructured":"Levine MH, Abt PL. Treatment options and strategies for antibody mediated rejection after renal transplantation. Semin Immunol. 2012;24(2):136\u201342.","journal-title":"Semin Immunol"},{"key":"292_CR49","doi-asserted-by":"crossref","unstructured":"Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1\u00a0year. Am J Transplant. 2015. doi: 10.1111\/ajt.13168 . [Epub ahead of print].","DOI":"10.1111\/ajt.13168"},{"issue":"1","key":"292_CR50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","volume":"95","author":"BD Tait","year":"2013","unstructured":"Tait BD, S\u00fcsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013;95(1):19\u201347.","journal-title":"Transplantation"},{"issue":"3","key":"292_CR51","doi-asserted-by":"crossref","first-page":"E293","DOI":"10.1111\/j.1399-0012.2012.01652.x","volume":"26","author":"S Dharancy","year":"2012","unstructured":"Dharancy S, Giral M, Tetaz R, Fatras M, Dubel L, Pageaux GP. Adherence with immunosuppressive treatment after transplantation: results from the French trial PREDICT. Clin Transpl. 2012;26(3):E293\u20139.","journal-title":"Clin Transpl"},{"issue":"6","key":"292_CR52","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1681\/ASN.2004121059","volume":"16","author":"FL Weng","year":"2005","unstructured":"Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol. 2005;16(6):1839\u201348.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"292_CR53","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1399-0012.2011.01544.x","volume":"26","author":"JM Morales","year":"2012","unstructured":"Morales JM, Varo E, L\u00e1zaro P. Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain. Clin Transpl. 2012;26(2):369\u201376.","journal-title":"Clin Transpl"},{"issue":"5","key":"292_CR54","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.transproceed.2008.02.083","volume":"40","author":"N Ichimaru","year":"2008","unstructured":"Ichimaru N, Kakuta Y, Abe T, et al. Treatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressants. Transpl Proc. 2008;40(5):1362\u20135.","journal-title":"Transpl Proc."},{"issue":"9","key":"292_CR55","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/j.1600-6143.2011.03571.x","volume":"11","author":"L Guirado","year":"2011","unstructured":"Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transpl. 2011;11(9):1965\u201371.","journal-title":"Am J Transpl"},{"issue":"2","key":"292_CR56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e3182725532","volume":"95","author":"DR Kuypers","year":"2013","unstructured":"Kuypers DR, Peeters PC, Sennesael JJ, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95(2):333\u201340.","journal-title":"Transplantation"},{"issue":"7","key":"292_CR57","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","volume":"21","author":"M Mohty","year":"2007","unstructured":"Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387\u201394.","journal-title":"Leukemia"},{"issue":"9","key":"292_CR58","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.TP.0000122187.76518.BC","volume":"77","author":"A Shah","year":"2004","unstructured":"Shah A, Nadasdy T, Arend L, et al. Treatment of C4d-positive acute humoral rejection with plasmapheresis and rabbit polyclonal antithymocyte globulin. Transplantation. 2004;77(9):1399\u2013405.","journal-title":"Transplantation"},{"issue":"1","key":"292_CR59","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-0012.2008.00902.x","volume":"23","author":"Z Kaposztas","year":"2009","unstructured":"Kaposztas Z, Podder H, Mauiyyedi S, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transpl. 2009;23(1):63\u201373.","journal-title":"Clin Transpl"},{"issue":"12","key":"292_CR60","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","volume":"86","author":"MJ Everly","year":"2008","unstructured":"Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008;86(12):1754\u201361.","journal-title":"Transplantation"},{"issue":"8","key":"292_CR61","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/j.1432-2277.2011.01290.x","volume":"24","author":"AR Biglarnia","year":"2011","unstructured":"Biglarnia AR, Nilsson B, Nilsson T, et al. Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation. Transpl Int. 2011;24(8):e61\u20136.","journal-title":"Transpl Int"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0292-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-016-0292-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0292-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T22:53:53Z","timestamp":1654383233000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0292-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,23]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["292"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0292-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,23]]}}}